Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program

Peter Iversen; Manfred P Wirth; William A See; David G McLeod; Ira Klimberg; Donald Gleason; Gerald Chodak; James Montie; Chris Tyrrell; D M A Wallace; Karl P J Delaere; Per Lundmo; Teuvo L J Tammela; Jan-Erik Johansson; Tom Morris; Kevin Carroll; Casodex Early Prostate Cancer Trialists' Group

doi:http://dx.doi.org/10.1016/j.urology.2004.02.011

Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program

Peter Iversen, Manfred P Wirth, William A See, David G McLeod, Ira Klimberg, Donald Gleason, Gerald Chodak, James Montie, Chris Tyrrell, D M A Wallace, Karl P J Delaere, Per Lundmo, Teuvo L J Tammela, Jan-Erik Johansson, Tom Morris, Kevin Carroll, Casodex Early Prostate Cancer Trialists' Group

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning

16 Citationer (Scopus)

Abstract

To report an exploratory subgroup analysis assessing the extent to which the overall benefit found in the Early Prostate Cancer program is dependent on lymph node status at randomization. The program is ongoing, and the overall survival data are immature. The first combined analysis of the bicalutamide (Casodex) Early Prostate Cancer program at 3 years' median follow-up showed that bicalutamide, 150 mg once daily, plus standard care (radical prostatectomy, radiotherapy, or watchful waiting), significantly reduced the risk of objective progression and prostate-specific antigen (PSA) doubling in patients with localized/locally advanced prostate cancer.

Originalsprog	Engelsk
Tidsskrift	Urology
Vol/bind	63
Udgave nummer	5
Sider (fra-til)	928-33
Antal sider	6
ISSN	0090-4295
DOI	https://doi.org/10.1016/j.urology.2004.02.011
Status	Udgivet - 1 maj 2004

Adgang til dokumentet

http://dx.doi.org/10.1016/j.urology.2004.02.011

Citationsformater

Iversen, P., Wirth, M. P., See, W. A., McLeod, D. G., Klimberg, I., Gleason, D., Chodak, G., Montie, J., Tyrrell, C., Wallace, D. M. A., Delaere, K. P. J., Lundmo, P., Tammela, T. L. J., Johansson, J-E., Morris, T., Carroll, K., & Casodex Early Prostate Cancer Trialists' Group (2004). Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program. Urology, 63(5), 928-33. https://doi.org/10.1016/j.urology.2004.02.011

Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program. / Iversen, Peter; Wirth, Manfred P; See, William A; McLeod, David G; Klimberg, Ira; Gleason, Donald; Chodak, Gerald; Montie, James; Tyrrell, Chris; Wallace, D M A; Delaere, Karl P J; Lundmo, Per; Tammela, Teuvo L J; Johansson, Jan-Erik; Morris, Tom; Carroll, Kevin; Casodex Early Prostate Cancer Trialists' Group.

I: Urology, Bind 63, Nr. 5, 01.05.2004, s. 928-33.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning

Iversen, P, Wirth, MP, See, WA, McLeod, DG, Klimberg, I, Gleason, D, Chodak, G, Montie, J, Tyrrell, C, Wallace, DMA, Delaere, KPJ, Lundmo, P, Tammela, TLJ, Johansson, J-E, Morris, T, Carroll, K & Casodex Early Prostate Cancer Trialists' Group 2004, 'Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program', Urology, bind 63, nr. 5, s. 928-33. https://doi.org/10.1016/j.urology.2004.02.011

Iversen, Peter ; Wirth, Manfred P ; See, William A ; McLeod, David G ; Klimberg, Ira ; Gleason, Donald ; Chodak, Gerald ; Montie, James ; Tyrrell, Chris ; Wallace, D M A ; Delaere, Karl P J ; Lundmo, Per ; Tammela, Teuvo L J ; Johansson, Jan-Erik ; Morris, Tom ; Carroll, Kevin ; Casodex Early Prostate Cancer Trialists' Group. / Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program. I: Urology. 2004 ; Bind 63, Nr. 5. s. 928-33.

@article{29e1ff883b8d488cbf396b6db68ba939,

title = "Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program",

abstract = "To report an exploratory subgroup analysis assessing the extent to which the overall benefit found in the Early Prostate Cancer program is dependent on lymph node status at randomization. The program is ongoing, and the overall survival data are immature. The first combined analysis of the bicalutamide (Casodex) Early Prostate Cancer program at 3 years' median follow-up showed that bicalutamide, 150 mg once daily, plus standard care (radical prostatectomy, radiotherapy, or watchful waiting), significantly reduced the risk of objective progression and prostate-specific antigen (PSA) doubling in patients with localized/locally advanced prostate cancer.",

author = "Peter Iversen and Wirth, {Manfred P} and See, {William A} and McLeod, {David G} and Ira Klimberg and Donald Gleason and Gerald Chodak and James Montie and Chris Tyrrell and Wallace, {D M A} and Delaere, {Karl P J} and Per Lundmo and Tammela, {Teuvo L J} and Jan-Erik Johansson and Tom Morris and Kevin Carroll and Peter Iversen",

year = "2004",

month = may,

day = "1",

doi = "http://dx.doi.org/10.1016/j.urology.2004.02.011",

language = "English",

volume = "63",

pages = "928--33",

journal = "Urology",

issn = "0090-4295",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program

AU - Iversen, Peter

AU - Wirth, Manfred P

AU - See, William A

AU - McLeod, David G

AU - Klimberg, Ira

AU - Gleason, Donald

AU - Chodak, Gerald

AU - Montie, James

AU - Tyrrell, Chris

AU - Wallace, D M A

AU - Delaere, Karl P J

AU - Lundmo, Per

AU - Tammela, Teuvo L J

AU - Johansson, Jan-Erik

AU - Morris, Tom

AU - Carroll, Kevin

AU - Casodex Early Prostate Cancer Trialists' Group

PY - 2004/5/1

Y1 - 2004/5/1

N2 - To report an exploratory subgroup analysis assessing the extent to which the overall benefit found in the Early Prostate Cancer program is dependent on lymph node status at randomization. The program is ongoing, and the overall survival data are immature. The first combined analysis of the bicalutamide (Casodex) Early Prostate Cancer program at 3 years' median follow-up showed that bicalutamide, 150 mg once daily, plus standard care (radical prostatectomy, radiotherapy, or watchful waiting), significantly reduced the risk of objective progression and prostate-specific antigen (PSA) doubling in patients with localized/locally advanced prostate cancer.

AB - To report an exploratory subgroup analysis assessing the extent to which the overall benefit found in the Early Prostate Cancer program is dependent on lymph node status at randomization. The program is ongoing, and the overall survival data are immature. The first combined analysis of the bicalutamide (Casodex) Early Prostate Cancer program at 3 years' median follow-up showed that bicalutamide, 150 mg once daily, plus standard care (radical prostatectomy, radiotherapy, or watchful waiting), significantly reduced the risk of objective progression and prostate-specific antigen (PSA) doubling in patients with localized/locally advanced prostate cancer.

U2 - http://dx.doi.org/10.1016/j.urology.2004.02.011

DO - http://dx.doi.org/10.1016/j.urology.2004.02.011

M3 - Journal article

VL - 63

SP - 928

EP - 933

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5

ER -